CRIZOTINIB

作品数：57被引量：92H指数：5
导出分析报告
相关领域：医药卫生更多>>
相关作者：王文娴周彩存周文菁李晓燕刘晓晴更多>>
相关机构：浙江大学上海市肺科医院浙江省肿瘤医院吉林省肿瘤医院更多>>
相关期刊：《临床合理用药》《World Journal of Clinical Cases》《World Journal of Clinical Oncology》《Cancer Communications》更多>>
相关基金：国家自然科学基金云南省教育厅科学研究基金云南省自然科学基金吉林省自然科学基金更多>>
-
在结果中检索

检索结果分析

结果分析中...
共 条 记 录，以下是1-10
全选清除导出
参考文献引证文献引用追踪
视图：
排序：
Therapeutic insights into epidermal growth factor receptor/reactive oxygen species proto-oncogene 1-receptor co-mutated non-small cell lung cancer:Crizotinib as a promising option
《World Journal of Clinical Oncology》2025年第3期190-193,共4页Yan Zhou Bo-Tao Xu Hai-Ying Zhou Zhong-Tu Shang 
This letter provides a review of the report by Peng et al on a unique case of non-small cell lung cancer(NSCLC),specifically lung adenocarcinoma,featuring reactive oxygen species proto-oncogene 1-receptor(ROS1)co-muta...
关键词：ADENOCARCINOMA CRIZOTINIB Genetic heterogeneity Lung cancer Mutation Personalized medicine 
Inhibiting the Otub1/phosphorylated STAT3 axis for the treatment of non-small cell lung cancer
《Acta Pharmacologica Sinica》2025年第1期184-195,共12页Zi-yang Liu Ya-wen Zhang Hai-xia Zhuang Yu-jie Qu Qiu-yun Jiang Ping-fei Li Yuan-ming He Yina Ren Xin-liana Mao 
This work was partly supported by Special Projects in Key Areas for Guangdong Provincial Colleges and Universities(#2021ZDZX2009 to XLM);the National Natural Science Foundation of China(#32100577 to YR);the Guangzhou Municipal Science and Technology Project(#202002030059 to XLM);by Guangzhou Medical University Discipline Construction Funds(Basic Medicine)(#JCXKJS2022A05 to XLM).
The transcription factor STAT3 is a promising target for the treatment of non-small cell lung cancer(NSCLC).STAT3 activity is mainly dependent on phosphorylation at tyrosine 705(pSTAT3-Y705),but the modulation on pSTA...
关键词：Otub1 STAT3 non-small cell lung cancer CRIZOTINIB 
Updated overall survival and circulating tumor DNA analysis of ensartinib for crizotinib-refractory ALK-positive NSCLC from a phase II study
《Cancer Communications》2024年第4期455-468,共14页Jing Zheng Tao Wang Yunpeng Yang Jie Huang Jifeng Feng Wu Zhuang Jianhua Chen Jun Zhao Wei Zhong Yanqiu Zhao Yiping Zhang Yong Song Yi Hu Zhuang Yu Youling Gong Yuan Chen Feng Ye Shucai Zhang Lejie Cao Yun Fan Gang Wu Yubiao Guo Chengzhi Zhou Kewei Ma Jian Fang Weineng Feng Yunpeng Liu Zhendong Zheng Gaofeng Li Huijie Wang Shundong Cang Ning Wu Wei Song Xiaoqing Liu Shijun Zhao Lieming Ding Giovanni Selvaggi Yang Wang Shanshan Xiao Qian Wang Zhilin Shen Jianya Zhou Jianying Zhou Li Zhang 
Background:The initial phase II stuty(NCT03215693)demonstrated that ensartinib has shown clinical activity in patients with advanced crizotinib-refractory,anaplastic lymphoma kinase(ALK)-positive non-small cell lung c...
关键词：anaplastic lymphoma kinase CTDNA ensartinib non-small cell lung cancer overall survival 
ALK inhibitors in cancer:mechanisms of resistance and therapeutic management strategies
《Cancer Drug Resistance》2024年第1期690-711,共22页Darin Poei Sana Ali Shirley Ye Robert Hsu 
Anaplastic lymphoma kinase(ALK)gene rearrangements have been identified as potent oncogenic drivers in several malignancies,including non-small cell lung cancer(NSCLC).The discovery of ALK inhibition using a tyrosine ...
关键词：NSCLC ALK TKI acquired resistance alectinib CRIZOTINIB lorlatinib ceritinib brigatinib 
Envonalkib versus crizotinib for treatment-naive ALK-positive non-small cell lung cancer: a randomized, multicenter, open-label, phase III trial被引量：6
《Signal Transduction and Targeted Therapy》2023年第9期4338-4345,共8页Yunpeng Yang Jie Min Nong Yang Qitao Yu Ying Cheng Yanqiu Zhao Manxiang Li Hong Chen Shou’an Ren Jianying Zhou Wu Zhuang Xintian Qin Lejie Cao Yan Yu Jian Zhang Jianxing He Jifeng Feng Hao Yu Li Zhang Wenfeng Fang 
This study was funded by the National Natural Science Foundation Project of China(Grant No.82072558).
Anaplastic lymphoma kinase(ALK)rearrangements are present in about 5–6%of non-small cell lung cancer(NSCLC)cases and associated with increased risks of central nervous system(CNS)involvement.Envonalkib,a novel ALK in...
关键词：CRIZOTINIB RANDOMIZED cancer 
Rare ROS1-CENPW gene in pancreatic acinar cell carcinoma and the effect of crizotinib plus AG chemotherapy:A case report
《World Journal of Clinical Cases》2023年第24期5823-5829,共7页Tao Wang Yi-Yu Shen 
BACKGROUND This is the first report of an ROS1-CENPW fusion gene in pancreatic malignancies.CASE SUMMARY A 77-year-old woman with a pancreatic tumor and multiple liver metastases was admitted to our hospital.Genetic t...
关键词：ROS1-CENPW Pancreatic acinar cell carcinoma CRIZOTINIB GEMCITABINE Albumin paclitaxel Case report 
Effective response to crizotinib of concurrent KIF5B-MET and MET-CDR2-rearranged non-small cell lung cancer:A case report被引量：1
《World Journal of Clinical Cases》2022年第8期2529-2536,共8页Lian-Fang Liu Jia-Ying Deng Analyn Lizaso Jing Lin Si Sun 
Supported by the National Key R&D Program of China;No. 2017YFC0907900 and 2017YFC0907904
BACKGROUND Due to the rarity of mesenchymal-epithelial transition factor(MET)fusions,the clinical efficacy of crizotinib has only been described in a few patients with MET fusions involving various fusion partners.Her...
关键词：Poorly differentiated Non-small cell carcinoma Mesenchymal-epithelial transition factor fusion CRIZOTINIB Case report 
A case report of response to crizotinib in chemotherapy-refractory metastatic gallbladder cancer with met amplification and acquired resistance resulting from the loss of MET amplification
《Precision Clinical Medicine》2021年第3期209-214,共6页Hongna Sun Xiaofen Li Shuang Dai Xudong Shen Meng Qiu 
This work was supported by the National Key Development Plan for Precision Medicine Research(Grant No.2017YFC0910004).
Gallbladder cancer(GBC)is a highly invasive disease and the most prevalent malignancy of the biliary system.Patients with GBC are commonly diagnosed at a late stage and have an unfavorable prognosis.Palliative chemoth...
关键词：metastatic gallbladder cancer MET amplification targeted therapy CTDNA acquired resistance case report 
Crizotinib对NSCLC裸鼠HGF表达影响及生存分析
《湖南师范大学学报（医学版）》2021年第4期117-120,共4页金岩 杨镇嘉 
目的:研究Crizotinib对非小细胞肺癌裸鼠肝细胞生长因子表达及生存情况影响。方法:我们将60只裸鼠分组造模后,用不同药物灌胃给药。比较药物治疗后三组大鼠的肿瘤生长情况,分析比较三组大鼠8周生存率,采用ELISA法测定治疗前后大鼠血清HG...
关键词：克里唑蒂尼 裸鼠 非小细胞肺癌 肝细胞生长因子 生存分析 
SAF-189s,a potent new-generation ROS1 inhibitor,is active against crizotinib-resistant ROS1 mutant-driven tumors被引量：1
《Acta Pharmacologica Sinica》2021年第6期998-1004,共7页Zong-jun Xia Yin-chun Ji De-qiao Sun Xia Peng Ying-lei Gao Yan-fen Fang Xing-dong Zhao Wei-bo Wang Jian Ding Mei-yu Geng Jing Ai 
This research was supported by grants from the"Personalized Medicines-Molecular Signature-based Drug Discovery and Development"Strategic Priority Research Program of the Chinese Academy of Sciences(Nos XDA12020000 for MYG and XDA12020103 for JA);the Natural Science Foundation of China for Innovation Research Group(No.81821005 for MYG);the Natural Science Foundation of China(Nos 81773762 and 81473243 for JA);the National Science&Technology Major Project"Key New Drug Creation and Manufacturing Program"of China(No.2018ZX09711002-011-013 for JA);the Collaborative Innovation Cluster Project of Shanghai Municipal Commission of Health and Family Planning(Grant 2019CXJQ02);the Collaborative Innovation Cluster Project of Shanghai Municipal Commission of Health and Family Planning(2020CXJQ02).
The ROS1 fusion kinase is an attractive antitumor target.Though with significant clinical efficacy,the well-known first-generation ROS1 inhibitor(ROS1i)crizotinib inevitably developed acquired resistance due to second...
关键词：ROS1 kinase ROS1 inhibitor SAF-189s lorlatinib crizotinib resistance G2032R mutant NSCLC 
全选清除导出
共6页<123456>
检索报告 对象比较 聚类工具 使用帮助 返回顶部